In real-world practice, Vyvgart (efgartigimod alfa) is generally well tolerated and often effective for adults with generalized myasthenia gravis (gMG) who are positive for antibodies against the acetylcholine receptor (AChR) protein, a study showed. However, responses vary across patients and are often not durable, data showed. “These findings highlight…
News
Cartesian Therapeutics’ experimental cell therapy Descartes-08 outperformed a placebo at easing symptoms of generalized myasthenia gravis (gMG) in patients who test positive for self-reactive antibodies targeting the acetylcholine receptor (AChR) protein. That’s according to a new subgroup analysis of the Phase 2b MG-001 clinical trial (NCT04146051). Previous…
Rystiggo (rozanolixizumab-noli) provides consistent symptom relief for people with generalized myasthenia gravis (gMG) across more than a dozen treatment cycles, according to a new analysis of clinical trial data. The approved UCB therapy is given as weekly subcutaneous, or under-the-skin, infusions in six-week cycles, with additional cycles…
At this year’s Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, researchers and clinicians are talking about the central role of patients, families, and caregivers in driving change for people living with neuromuscular diseases. Bionews, the parent company of this site, sat down with John F. Crowley, president and…
Johnson & Johnson (J&J) has launched a Phase 3b clinical trial to compare the efficacy of two approved treatments for generalized myasthenia gravis (gMG). The trial, dubbed EPIC (NCT07217587), is specifically testing J&J’s Imaavy (nipocalimab) against Argenx’s Vyvgart (efgartigimod) in adults with gMG who…
Recovery after a myasthenia gravis (MG) exacerbation — a flare up or sudden worsening of disease symptoms — may take many months, even with the newer treatment options now available to MG patients. That’s according to a small study in Germany that followed 12 people with MG, treated with…
People with myasthenia gravis (MG) have higher psychological distress, including depression and anxiety, more frequent sleep problems, and greater cognitive difficulties than healthy people, according to a study in Italy. In addition, more severe disease and treatment with higher doses of corticosteroids were independent predictors of psychiatric symptoms…
Four weekly under-the-skin injections of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) led to a marked reduction in double vision and drooping eyelids in adults with ocular myasthenia gravis (MG), according to top-line Phase 3 results. These findings come from the global Phase 3 ADAPT OCULUS clinical trial (NCT06558279),…
Next week, researchers, clinicians, industry leaders, and families will gather at the 2026 MDA Clinical & Scientific Conference, hosted by the Muscular Dystrophy Association (MDA), to discuss the latest advances in neuromuscular disease research and care. Ahead of the event, Bionews, the parent company of this site, sat…
While certain medications are typically avoided in myasthenia gravis (MG), a large-scale study from France suggests that cholesterol-lowering statins may actually reduce the overall risk of death in these patients. The research indicates that although statins can slightly increase the short-term chance of a severe symptom flare-up, their…
Recent Posts
- I want to reach for acceptance, but right now, I’m just reaching for a cigarette
- Diabetes may worsen MG by activating antibody-producing cells
- What courage looks like in daily life with myasthenia gravis
- Global clinical trial launches to test self-given, long-acting gMG drug
- Living well with MG means planning, self-awareness, asking for help